Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The herpes simplex virus (HSV) helicase–primase complex is a multi-protein enzyme essential for viral DNA replication. It comprises the UL5 (helicase), UL52 (primase), and UL8 (non-catalytic) subunits. This complex unwinds double-stranded DNA and synthesizes RNA primers necessary for DNA synthesis. It is a validated antiviral target, with inhibitors like pritelivir demonstrating efficacy against HSV infections, including acyclovir-resistant strains. Resistance mutations often map to specific residues in the catalytic domains of UL5 and UL52. Targeting this complex offers an alternative strategy against drug-resistant strains by blocking essential steps upstream in genome processing.
Inhibition of helicase and/or primase activity, thereby blocking viral DNA replication.
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Herpes Simplex Virus Helicase–Primase Complex (HSV Helicase-Primase).